Blueprint Medicines

BPMC69

$94.63arrow_drop_up0.84%$0.78

BPMC69

$94.63

arrow_drop_up0.84%$0.78

Performance History

Key Stats
Open	$93.86
Prev. Close	$93.87
EPS	-2.09
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	89.03	95.43
52 Week Range	43.89	121.90

Ratios







EPS	-2.09

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Blueprint Medicines (BPMC)

Blueprint Medicines Corp (BPMC) is a biopharmaceutical company that focuses on discovering, developing, and commercializing precision therapies for patients with genomically defined cancers and rare diseases. The company’s goal is to transform the lives of patients by targeting the underlying genetic drivers of their diseases. Through its proprietary platform, Blueprint Medicines identifies and develops highly selective kinase inhibitors that have the potential to address significant unmet needs in oncology and other therapeutic areas.

As of the latest stock price history, Blueprint Medicines Corp's stock (BPMC) has shown significant growth over the years. The stock has experienced ups and downs, but the overall trend has been positive. Investors have shown interest in the company due to its innovative approach to precision medicine and its potential to address unmet medical needs. The stock price has been influenced by various factors such as clinical trial results, regulatory approvals, and market trends.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Ms. Kathryn Haviland
Headquarters: Cambridge
Employees: 660
Exchange: NASDAQ

Keep an eye on Blueprint Medicines

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Blueprint Medicines's (BPMC) price per share?

The current price per share for Blueprint Medicines (BPMC) is $94.63. The stock has seen a price change of $0.79 recently, indicating a 0.84% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Blueprint Medicines (BPMC)?

For Blueprint Medicines (BPMC), the 52-week high is $121.9, which is 28.82% from the current price. The 52-week low is $43.89, the current price is 115.61% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Blueprint Medicines (BPMC) a growth stock?

Blueprint Medicines (BPMC) has shown an average price growth of -3.4% over the past three years. It has received a score of 63 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Blueprint Medicines as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Blueprint Medicines (BPMC) stock price performance year to date (YTD)?

As of the latest data, Blueprint Medicines (BPMC) has a year-to-date price change of 3.91%. Over the past month, the stock has experienced a price change of 14.33%. Over the last three months, the change has been -0.47%. Over the past six months, the figure is -7.55%. Looking at a longer horizon, the five-year price change stands at 20.27%.

help

Is Blueprint Medicines (BPMC) a profitable company?

Blueprint Medicines (BPMC) has a net income of -$506.98M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 94.87% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -38.21% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $249.38M, with a revenue growth rate of 22.22%, providing insight into the company's sales performance and growth. The gross profit is $236.58M. Operating income is noted at -$486.28M. Furthermore, the EBITDA is -$262.13M.

help

What is the market capitalization of Blueprint Medicines (BPMC)?

Blueprint Medicines (BPMC) has a market capitalization of $5.93B. The average daily trading volume is 94.09, indicating the stock's liquidity and investor engagement.